nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexmedetomidine—CYP1A2—Carmustine—malignant glioma	0.327	1	CbGbCtD
Dexmedetomidine—Disorder sight—Temozolomide—malignant glioma	0.0142	0.0427	CcSEcCtD
Dexmedetomidine—Rigors—Temozolomide—malignant glioma	0.00831	0.0249	CcSEcCtD
Dexmedetomidine—Gamma-glutamyltransferase increased—Temozolomide—malignant glioma	0.00825	0.0247	CcSEcCtD
Dexmedetomidine—Speech disorder—Carmustine—malignant glioma	0.00816	0.0245	CcSEcCtD
Dexmedetomidine—Speech disorder—Temozolomide—malignant glioma	0.00789	0.0236	CcSEcCtD
Dexmedetomidine—Leukocytosis—Carmustine—malignant glioma	0.00747	0.0224	CcSEcCtD
Dexmedetomidine—Hyperbilirubinaemia—Temozolomide—malignant glioma	0.00746	0.0224	CcSEcCtD
Dexmedetomidine—Respiratory failure—Temozolomide—malignant glioma	0.00691	0.0207	CcSEcCtD
Dexmedetomidine—Phosphatase alkaline increased—Temozolomide—malignant glioma	0.00678	0.0203	CcSEcCtD
Dexmedetomidine—Abnormal vision—Carmustine—malignant glioma	0.00612	0.0184	CcSEcCtD
Dexmedetomidine—Sepsis—Carmustine—malignant glioma	0.00609	0.0183	CcSEcCtD
Dexmedetomidine—Abnormal vision—Temozolomide—malignant glioma	0.00592	0.0177	CcSEcCtD
Dexmedetomidine—Blood alkaline phosphatase increased—Temozolomide—malignant glioma	0.00566	0.017	CcSEcCtD
Dexmedetomidine—Thirst—Temozolomide—malignant glioma	0.00517	0.0155	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Carmustine—malignant glioma	0.00464	0.0139	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Temozolomide—malignant glioma	0.00448	0.0134	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.00443	0.0133	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.00434	0.013	CcSEcCtD
Dexmedetomidine—Abdominal distension—Temozolomide—malignant glioma	0.00428	0.0128	CcSEcCtD
Dexmedetomidine—Sweating increased—Temozolomide—malignant glioma	0.00415	0.0124	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Carmustine—malignant glioma	0.00397	0.0119	CcSEcCtD
Dexmedetomidine—Pneumonia—Carmustine—malignant glioma	0.00395	0.0118	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Carmustine—malignant glioma	0.00385	0.0115	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Temozolomide—malignant glioma	0.00384	0.0115	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Carmustine—malignant glioma	0.00382	0.0114	CcSEcCtD
Dexmedetomidine—Pneumonia—Temozolomide—malignant glioma	0.00382	0.0114	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Temozolomide—malignant glioma	0.00372	0.0112	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Temozolomide—malignant glioma	0.00369	0.0111	CcSEcCtD
Dexmedetomidine—Haemoglobin—Carmustine—malignant glioma	0.00354	0.0106	CcSEcCtD
Dexmedetomidine—Haemorrhage—Carmustine—malignant glioma	0.00352	0.0106	CcSEcCtD
Dexmedetomidine—Hallucination—Carmustine—malignant glioma	0.00351	0.0105	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Carmustine—malignant glioma	0.00347	0.0104	CcSEcCtD
Dexmedetomidine—Haemoglobin—Temozolomide—malignant glioma	0.00342	0.0103	CcSEcCtD
Dexmedetomidine—Haemorrhage—Temozolomide—malignant glioma	0.00341	0.0102	CcSEcCtD
Dexmedetomidine—Visual impairment—Carmustine—malignant glioma	0.0034	0.0102	CcSEcCtD
Dexmedetomidine—Hallucination—Temozolomide—malignant glioma	0.00339	0.0102	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Temozolomide—malignant glioma	0.00336	0.0101	CcSEcCtD
Dexmedetomidine—Visual impairment—Temozolomide—malignant glioma	0.00328	0.00984	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Temozolomide—malignant glioma	0.00316	0.00948	CcSEcCtD
Dexmedetomidine—Arrhythmia—Carmustine—malignant glioma	0.00315	0.00944	CcSEcCtD
Dexmedetomidine—Angiopathy—Temozolomide—malignant glioma	0.00309	0.00926	CcSEcCtD
Dexmedetomidine—Mental disorder—Carmustine—malignant glioma	0.00309	0.00926	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Temozolomide—malignant glioma	0.00307	0.0092	CcSEcCtD
Dexmedetomidine—Malnutrition—Carmustine—malignant glioma	0.00307	0.0092	CcSEcCtD
Dexmedetomidine—Chills—Temozolomide—malignant glioma	0.00306	0.00916	CcSEcCtD
Dexmedetomidine—Mental disorder—Temozolomide—malignant glioma	0.00298	0.00895	CcSEcCtD
Dexmedetomidine—Malnutrition—Temozolomide—malignant glioma	0.00297	0.00889	CcSEcCtD
Dexmedetomidine—Anaemia—Carmustine—malignant glioma	0.00284	0.0085	CcSEcCtD
Dexmedetomidine—Agitation—Carmustine—malignant glioma	0.00282	0.00845	CcSEcCtD
Dexmedetomidine—Anaemia—Temozolomide—malignant glioma	0.00274	0.00822	CcSEcCtD
Dexmedetomidine—Agitation—Temozolomide—malignant glioma	0.00273	0.00817	CcSEcCtD
Dexmedetomidine—Convulsion—Carmustine—malignant glioma	0.00266	0.00797	CcSEcCtD
Dexmedetomidine—Hypertension—Carmustine—malignant glioma	0.00265	0.00794	CcSEcCtD
Dexmedetomidine—Anxiety—Carmustine—malignant glioma	0.0026	0.0078	CcSEcCtD
Dexmedetomidine—Convulsion—Temozolomide—malignant glioma	0.00257	0.0077	CcSEcCtD
Dexmedetomidine—Hypertension—Temozolomide—malignant glioma	0.00256	0.00767	CcSEcCtD
Dexmedetomidine—Confusional state—Carmustine—malignant glioma	0.00253	0.00757	CcSEcCtD
Dexmedetomidine—Anxiety—Temozolomide—malignant glioma	0.00252	0.00754	CcSEcCtD
Dexmedetomidine—Infection—Carmustine—malignant glioma	0.00249	0.00746	CcSEcCtD
Dexmedetomidine—Dry mouth—Temozolomide—malignant glioma	0.00247	0.0074	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Carmustine—malignant glioma	0.00245	0.00735	CcSEcCtD
Dexmedetomidine—Tachycardia—Carmustine—malignant glioma	0.00244	0.00733	CcSEcCtD
Dexmedetomidine—Confusional state—Temozolomide—malignant glioma	0.00244	0.00732	CcSEcCtD
Dexmedetomidine—Infection—Temozolomide—malignant glioma	0.0024	0.00721	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Temozolomide—malignant glioma	0.00237	0.0071	CcSEcCtD
Dexmedetomidine—Hypotension—Carmustine—malignant glioma	0.00234	0.00702	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Temozolomide—malignant glioma	0.00234	0.00701	CcSEcCtD
Dexmedetomidine—Dyspnoea—Carmustine—malignant glioma	0.00223	0.00669	CcSEcCtD
Dexmedetomidine—Somnolence—Carmustine—malignant glioma	0.00223	0.00667	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Carmustine—malignant glioma	0.00216	0.00648	CcSEcCtD
Dexmedetomidine—Dyspnoea—Temozolomide—malignant glioma	0.00216	0.00647	CcSEcCtD
Dexmedetomidine—Somnolence—Temozolomide—malignant glioma	0.00215	0.00645	CcSEcCtD
Dexmedetomidine—Constipation—Carmustine—malignant glioma	0.00214	0.00642	CcSEcCtD
Dexmedetomidine—Pain—Carmustine—malignant glioma	0.00214	0.00642	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Temozolomide—malignant glioma	0.00209	0.00626	CcSEcCtD
Dexmedetomidine—Constipation—Temozolomide—malignant glioma	0.00207	0.0062	CcSEcCtD
Dexmedetomidine—Pain—Temozolomide—malignant glioma	0.00207	0.0062	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Carmustine—malignant glioma	0.00206	0.00619	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Carmustine—malignant glioma	0.00205	0.00614	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Temozolomide—malignant glioma	0.00199	0.00598	CcSEcCtD
Dexmedetomidine—Body temperature increased—Carmustine—malignant glioma	0.00198	0.00593	CcSEcCtD
Dexmedetomidine—Abdominal pain—Carmustine—malignant glioma	0.00198	0.00593	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Temozolomide—malignant glioma	0.00198	0.00593	CcSEcCtD
Dexmedetomidine—Body temperature increased—Temozolomide—malignant glioma	0.00191	0.00574	CcSEcCtD
Dexmedetomidine—Abdominal pain—Temozolomide—malignant glioma	0.00191	0.00574	CcSEcCtD
Dexmedetomidine—Diarrhoea—Carmustine—malignant glioma	0.00171	0.00514	CcSEcCtD
Dexmedetomidine—Dizziness—Carmustine—malignant glioma	0.00166	0.00496	CcSEcCtD
Dexmedetomidine—Diarrhoea—Temozolomide—malignant glioma	0.00166	0.00496	CcSEcCtD
Dexmedetomidine—Dizziness—Temozolomide—malignant glioma	0.0016	0.0048	CcSEcCtD
Dexmedetomidine—Vomiting—Carmustine—malignant glioma	0.00159	0.00477	CcSEcCtD
Dexmedetomidine—Rash—Carmustine—malignant glioma	0.00158	0.00473	CcSEcCtD
Dexmedetomidine—Dermatitis—Carmustine—malignant glioma	0.00158	0.00473	CcSEcCtD
Dexmedetomidine—Headache—Carmustine—malignant glioma	0.00157	0.0047	CcSEcCtD
Dexmedetomidine—Vomiting—Temozolomide—malignant glioma	0.00154	0.00461	CcSEcCtD
Dexmedetomidine—Rash—Temozolomide—malignant glioma	0.00153	0.00457	CcSEcCtD
Dexmedetomidine—Dermatitis—Temozolomide—malignant glioma	0.00152	0.00457	CcSEcCtD
Dexmedetomidine—Headache—Temozolomide—malignant glioma	0.00152	0.00454	CcSEcCtD
Dexmedetomidine—Nausea—Carmustine—malignant glioma	0.00149	0.00446	CcSEcCtD
Dexmedetomidine—Nausea—Temozolomide—malignant glioma	0.00144	0.00431	CcSEcCtD
Dexmedetomidine—ADRA2C—Signaling Pathways—KDR—malignant glioma	5.29e-05	0.000156	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—AKT2—malignant glioma	5.28e-05	0.000156	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—TP53—malignant glioma	5.27e-05	0.000155	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CAV1—malignant glioma	5.26e-05	0.000155	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—EGFR—malignant glioma	5.26e-05	0.000155	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—RAF1—malignant glioma	5.26e-05	0.000155	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CD80—malignant glioma	5.22e-05	0.000154	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—APC—malignant glioma	5.21e-05	0.000154	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CG—malignant glioma	5.21e-05	0.000154	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—KDR—malignant glioma	5.2e-05	0.000153	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—CAV1—malignant glioma	5.19e-05	0.000153	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—IL2—malignant glioma	5.19e-05	0.000153	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PTGS1—malignant glioma	5.17e-05	0.000152	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	5.15e-05	0.000152	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—EGF—malignant glioma	5.15e-05	0.000152	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—PIK3CB—malignant glioma	5.13e-05	0.000151	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PTPN11—malignant glioma	5.12e-05	0.000151	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PIK3CD—malignant glioma	5.12e-05	0.000151	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PDGFRA—malignant glioma	5.1e-05	0.00015	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—F2—malignant glioma	5.09e-05	0.00015	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—FN1—malignant glioma	5.09e-05	0.00015	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PIK3CD—malignant glioma	5.08e-05	0.00015	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—BAD—malignant glioma	5.03e-05	0.000148	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—PIK3CA—malignant glioma	5.03e-05	0.000148	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—F2—malignant glioma	5.01e-05	0.000148	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—FN1—malignant glioma	5.01e-05	0.000148	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—NOTCH1—malignant glioma	4.98e-05	0.000147	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—KRAS—malignant glioma	4.97e-05	0.000146	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—SPP1—malignant glioma	4.95e-05	0.000146	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—BAD—malignant glioma	4.95e-05	0.000146	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—CXCL8—malignant glioma	4.93e-05	0.000145	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—NOTCH1—malignant glioma	4.9e-05	0.000144	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—BRAF—malignant glioma	4.9e-05	0.000144	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CD80—malignant glioma	4.88e-05	0.000144	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—APC—malignant glioma	4.87e-05	0.000143	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CG—malignant glioma	4.87e-05	0.000143	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—FGF2—malignant glioma	4.86e-05	0.000143	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—EGF—malignant glioma	4.81e-05	0.000142	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—BCHE—malignant glioma	4.81e-05	0.000142	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CD80—malignant glioma	4.8e-05	0.000141	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CG—malignant glioma	4.79e-05	0.000141	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—APC—malignant glioma	4.79e-05	0.000141	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PTPN11—malignant glioma	4.78e-05	0.000141	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—AKT2—malignant glioma	4.77e-05	0.000141	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CAV1—malignant glioma	4.77e-05	0.000141	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—SLC5A5—malignant glioma	4.75e-05	0.00014	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—EGFR—malignant glioma	4.75e-05	0.00014	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—EGF—malignant glioma	4.74e-05	0.00014	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CG—malignant glioma	4.73e-05	0.000139	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—IL2—malignant glioma	4.71e-05	0.000139	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PTPN11—malignant glioma	4.71e-05	0.000139	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TERT—malignant glioma	4.69e-05	0.000138	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CD—malignant glioma	4.58e-05	0.000135	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PDGFB—malignant glioma	4.58e-05	0.000135	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—BRAF—malignant glioma	4.58e-05	0.000135	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—PIK3CA—malignant glioma	4.57e-05	0.000135	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PPARG—malignant glioma	4.57e-05	0.000135	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—FGFR1—malignant glioma	4.56e-05	0.000134	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MDM2—malignant glioma	4.55e-05	0.000134	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—PIK3CA—malignant glioma	4.54e-05	0.000134	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—RAF1—malignant glioma	4.53e-05	0.000134	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GSTP1—malignant glioma	4.52e-05	0.000133	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—BRAF—malignant glioma	4.5e-05	0.000133	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—CAV1—malignant glioma	4.5e-05	0.000132	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	4.49e-05	0.000132	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—HIF1A—malignant glioma	4.49e-05	0.000132	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—KRAS—malignant glioma	4.49e-05	0.000132	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—ERBB2—malignant glioma	4.48e-05	0.000132	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PIK3CB—malignant glioma	4.46e-05	0.000131	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—AKT2—malignant glioma	4.46e-05	0.000131	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—AKT1—malignant glioma	4.45e-05	0.000131	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	4.45e-05	0.000131	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—EGFR—malignant glioma	4.44e-05	0.000131	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PIK3CB—malignant glioma	4.42e-05	0.00013	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PTGS2—malignant glioma	4.42e-05	0.00013	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CAT—malignant glioma	4.4e-05	0.00013	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—FGF2—malignant glioma	4.39e-05	0.000129	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—AKT2—malignant glioma	4.39e-05	0.000129	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—EGFR—malignant glioma	4.37e-05	0.000129	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CG—malignant glioma	4.34e-05	0.000128	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CAV1—malignant glioma	4.34e-05	0.000128	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	4.3e-05	0.000127	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—KDR—malignant glioma	4.29e-05	0.000127	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CD—malignant glioma	4.28e-05	0.000126	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CXCL8—malignant glioma	4.25e-05	0.000125	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—PIK3CA—malignant glioma	4.24e-05	0.000125	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CD—malignant glioma	4.21e-05	0.000124	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PPARG—malignant glioma	4.19e-05	0.000124	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—KRAS—malignant glioma	4.19e-05	0.000123	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—PIK3CA—malignant glioma	4.17e-05	0.000123	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CD—malignant glioma	4.16e-05	0.000123	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—NCOR1—malignant glioma	4.15e-05	0.000122	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—F2—malignant glioma	4.13e-05	0.000122	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—FN1—malignant glioma	4.13e-05	0.000122	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—KRAS—malignant glioma	4.12e-05	0.000122	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—PIK3CA—malignant glioma	4.12e-05	0.000121	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—AKT1—malignant glioma	4.11e-05	0.000121	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MDM2—malignant glioma	4.11e-05	0.000121	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—FGF2—malignant glioma	4.1e-05	0.000121	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CG—malignant glioma	4.1e-05	0.000121	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—RAF1—malignant glioma	4.09e-05	0.000121	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—BAD—malignant glioma	4.08e-05	0.00012	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CASP3—malignant glioma	4.07e-05	0.00012	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IL2—malignant glioma	4.06e-05	0.00012	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—ERBB2—malignant glioma	4.05e-05	0.000119	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NOTCH1—malignant glioma	4.04e-05	0.000119	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—FGF2—malignant glioma	4.03e-05	0.000119	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CB—malignant glioma	3.99e-05	0.000118	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CD80—malignant glioma	3.96e-05	0.000117	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—APC—malignant glioma	3.96e-05	0.000117	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CG—malignant glioma	3.96e-05	0.000117	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PPARG—malignant glioma	3.95e-05	0.000116	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EGF—malignant glioma	3.91e-05	0.000115	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PTPN11—malignant glioma	3.89e-05	0.000115	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	3.88e-05	0.000114	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PTEN—malignant glioma	3.86e-05	0.000114	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—PIK3CA—malignant glioma	3.85e-05	0.000113	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MMP9—malignant glioma	3.85e-05	0.000113	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CXCL8—malignant glioma	3.84e-05	0.000113	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MDM2—malignant glioma	3.84e-05	0.000113	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GSTP1—malignant glioma	3.83e-05	0.000113	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PTEN—malignant glioma	3.82e-05	0.000113	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—RAF1—malignant glioma	3.82e-05	0.000113	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CD—malignant glioma	3.82e-05	0.000113	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—PIK3CA—malignant glioma	3.79e-05	0.000112	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—ERBB2—malignant glioma	3.78e-05	0.000111	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MDM2—malignant glioma	3.77e-05	0.000111	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—RAF1—malignant glioma	3.76e-05	0.000111	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CB—malignant glioma	3.73e-05	0.00011	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—AKT1—malignant glioma	3.73e-05	0.00011	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CAT—malignant glioma	3.72e-05	0.00011	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—ERBB2—malignant glioma	3.72e-05	0.00011	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—BRAF—malignant glioma	3.72e-05	0.00011	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—AKT1—malignant glioma	3.71e-05	0.000109	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CASP3—malignant glioma	3.67e-05	0.000108	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CB—malignant glioma	3.67e-05	0.000108	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IL2—malignant glioma	3.67e-05	0.000108	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CB—malignant glioma	3.62e-05	0.000107	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—AKT2—malignant glioma	3.62e-05	0.000107	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—EGFR—malignant glioma	3.6e-05	0.000106	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CD—malignant glioma	3.6e-05	0.000106	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PTGS2—malignant glioma	3.59e-05	0.000106	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CXCL8—malignant glioma	3.59e-05	0.000106	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CXCL8—malignant glioma	3.53e-05	0.000104	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—NCOR1—malignant glioma	3.52e-05	0.000104	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CD—malignant glioma	3.48e-05	0.000102	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MMP9—malignant glioma	3.47e-05	0.000102	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—AKT1—malignant glioma	3.46e-05	0.000102	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—VEGFA—malignant glioma	3.45e-05	0.000102	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PTEN—malignant glioma	3.45e-05	0.000102	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—PIK3CA—malignant glioma	3.44e-05	0.000101	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CASP3—malignant glioma	3.43e-05	0.000101	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IL2—malignant glioma	3.43e-05	0.000101	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—STAT3—malignant glioma	3.42e-05	0.000101	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—AKT1—malignant glioma	3.41e-05	0.0001	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—KRAS—malignant glioma	3.4e-05	0.0001	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CAV1—malignant glioma	3.38e-05	9.97e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CASP3—malignant glioma	3.38e-05	9.95e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IL2—malignant glioma	3.37e-05	9.94e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—AKT1—malignant glioma	3.37e-05	9.92e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—FGF2—malignant glioma	3.33e-05	9.81e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CB—malignant glioma	3.33e-05	9.81e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PTGS2—malignant glioma	3.3e-05	9.72e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MMP9—malignant glioma	3.24e-05	9.56e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PTEN—malignant glioma	3.22e-05	9.5e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MMP9—malignant glioma	3.19e-05	9.41e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MYC—malignant glioma	3.18e-05	9.36e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PTEN—malignant glioma	3.17e-05	9.35e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—AKT1—malignant glioma	3.15e-05	9.27e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CB—malignant glioma	3.14e-05	9.25e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PTEN—malignant glioma	3.13e-05	9.23e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—PIK3CA—malignant glioma	3.13e-05	9.22e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—VEGFA—malignant glioma	3.12e-05	9.19e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MDM2—malignant glioma	3.12e-05	9.18e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PTGS2—malignant glioma	3.11e-05	9.16e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—EGFR—malignant glioma	3.11e-05	9.16e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—RAF1—malignant glioma	3.1e-05	9.15e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—AKT1—malignant glioma	3.1e-05	9.12e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—STAT3—malignant glioma	3.09e-05	9.1e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CG—malignant glioma	3.08e-05	9.08e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ERBB2—malignant glioma	3.07e-05	9.05e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CB—malignant glioma	3.03e-05	8.93e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PPARG—malignant glioma	2.97e-05	8.77e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—KRAS—malignant glioma	2.94e-05	8.65e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CXCL8—malignant glioma	2.91e-05	8.58e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—VEGFA—malignant glioma	2.91e-05	8.58e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—STAT3—malignant glioma	2.88e-05	8.5e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PTEN—malignant glioma	2.88e-05	8.47e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MYC—malignant glioma	2.87e-05	8.45e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CAV1—malignant glioma	2.87e-05	8.45e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—VEGFA—malignant glioma	2.87e-05	8.45e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—STAT3—malignant glioma	2.84e-05	8.36e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—AKT1—malignant glioma	2.81e-05	8.29e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—EGFR—malignant glioma	2.81e-05	8.27e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CASP3—malignant glioma	2.79e-05	8.21e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL2—malignant glioma	2.78e-05	8.2e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	2.74e-05	8.07e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PIK3CA—malignant glioma	2.72e-05	8.02e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PTEN—malignant glioma	2.71e-05	7.99e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CD—malignant glioma	2.71e-05	7.98e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PIK3CA—malignant glioma	2.7e-05	7.95e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MYC—malignant glioma	2.68e-05	7.9e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—KRAS—malignant glioma	2.65e-05	7.81e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MYC—malignant glioma	2.64e-05	7.77e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MMP9—malignant glioma	2.63e-05	7.76e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—EGFR—malignant glioma	2.62e-05	7.72e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PTEN—malignant glioma	2.62e-05	7.72e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CG—malignant glioma	2.61e-05	7.69e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TP53—malignant glioma	2.61e-05	7.69e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—EGFR—malignant glioma	2.58e-05	7.6e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—AKT1—malignant glioma	2.56e-05	7.53e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PPARG—malignant glioma	2.52e-05	7.43e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—KRAS—malignant glioma	2.48e-05	7.3e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—KRAS—malignant glioma	2.44e-05	7.18e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CA—malignant glioma	2.44e-05	7.18e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—VEGFA—malignant glioma	2.37e-05	6.97e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CB—malignant glioma	2.36e-05	6.96e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TP53—malignant glioma	2.36e-05	6.94e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—STAT3—malignant glioma	2.34e-05	6.9e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PTGS2—malignant glioma	2.34e-05	6.9e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CD—malignant glioma	2.3e-05	6.76e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CA—malignant glioma	2.27e-05	6.7e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CA—malignant glioma	2.24e-05	6.6e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—AKT1—malignant glioma	2.22e-05	6.55e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CA—malignant glioma	2.21e-05	6.51e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—AKT1—malignant glioma	2.2e-05	6.49e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TP53—malignant glioma	2.2e-05	6.48e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MYC—malignant glioma	2.18e-05	6.41e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TP53—malignant glioma	2.17e-05	6.38e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EGFR—malignant glioma	2.13e-05	6.27e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PTEN—malignant glioma	2.04e-05	6.01e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CA—malignant glioma	2.03e-05	5.98e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—KRAS—malignant glioma	2.01e-05	5.93e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CB—malignant glioma	2e-05	5.9e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—AKT1—malignant glioma	1.99e-05	5.86e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PTGS2—malignant glioma	1.98e-05	5.84e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CA—malignant glioma	1.91e-05	5.64e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—AKT1—malignant glioma	1.86e-05	5.48e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CA—malignant glioma	1.85e-05	5.44e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—AKT1—malignant glioma	1.83e-05	5.39e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—AKT1—malignant glioma	1.81e-05	5.32e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TP53—malignant glioma	1.79e-05	5.27e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PTEN—malignant glioma	1.73e-05	5.09e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—AKT1—malignant glioma	1.66e-05	4.88e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—AKT1—malignant glioma	1.56e-05	4.6e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—AKT1—malignant glioma	1.51e-05	4.45e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CA—malignant glioma	1.44e-05	4.24e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CA—malignant glioma	1.22e-05	3.59e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—AKT1—malignant glioma	1.18e-05	3.47e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—AKT1—malignant glioma	9.96e-06	2.94e-05	CbGpPWpGaD
